The Zhitong Finance App learned that Lyon released a research report saying that Cinda Biotech (01801) announced on July 14 that it has authorized the rights of its immunological drug iBi355 outside of Greater China to Spero Therapeutics, with a total transaction amount of 1.1 billion US dollars. The bank believes that although the scale of this deal is smaller than the other two deals reached at the beginning of this year, the latest deal once again reflects Cinda Biotech's R&D strength. Lyon raised Cinda Biotech's target price from HK$135.8 to HK$139.9, maintaining the “outperforming the market” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.